News | January 21, 2010

Interventional Treatment Short-Circuits Hypertension

The Symplicity Catheter System manufactured by Ardian Inc. delivers radio frequency (RF) energy from within the renal artery to block conduction in the surrounding renal nerves.

January 21, 2010 – A new minimally invasive therapy using radiofrequency ablation to short-circuit nerves in the kidney arteries shows promise in treating uncontrolled hypertension. The research was presented this week at the International Symposium on Endovascular Therapy (ISET).

In a study of 70 patients, who had uncontrolled hypertension despite taking three or more blood pressure medications, underwent the procedure, called sympathetic renal denervation (RDN). One month after treatment, the average decrease in systolic blood pressure was 18 mmHg and in diastolic blood pressure was 11 mmHg. Blood pressure continued to improve, and the 34 patients who have reached 12-month follow-up had an average decrease in systolic blood pressure of 27 mmHg and in diastolic blood pressure of 11 mmHg.

“This treatment may help people who have the worst of the worst disease – who have hypertension that medications just can’t control and who are most likely to suffer from stroke and heart disease,” said Krishna Rocha-Singh, M.D., medical director of Prairie Vascular Institute, Springfield, Illinois, who is presenting results at ISET. “There are broader implications of this procedure, such as the possibility of using it to address other conditions, such as chronic kidney disease and heart failure. Another hope is that we eventually may be able to use this therapy to help patients with mild to moderate hypertension, without the use of drug therapy.”

Blood pressure is controlled by a combination of nerve signals and hormonal interactions between the brain, heart, blood vessels and kidneys. Hyperactive nerve signals from the kidneys may be a main cause of hypertension in many people. The nerves traveling to the kidneys are a key final common pathway needed to raise blood pressure. RDN treatment is used to interrupt these hyperactive signals between the kidney and the brain, leading to lower blood pressure. In the procedure, a tiny incision is made in the groin artery and a thin tube (catheter) with an electrode on the tip is inserted and advanced to the kidney arteries. The electrode is placed at up to six points along each artery, and low-dose radiofrequency energy is delivered to disable the surrounding nerves.

The kidneys play a central role in the long-term control of blood pressure, so the kidney is a major target of medicines used to control hypertension. However, more than a third of the 75 million Americans with hypertension are unable to control the condition, despite taking medication.

For more information: www.ISET.org

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init